
    
      The primary objective is to evaluate the sCR rate of the combination of carfilzomib,
      lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients at the completion
      of consolidation therapy.

      It's a multicenter, open label, non randomized, phase II study. 46 patients will be enrolled.

      Induction: 4 cycles of 28 Days with Carfilzomib/Lenalidomide and dexamethasone Stem Cell
      Harvest: High dose Cyclophosphamide with intensification consolidation: 4 cycles of 28 Days
      with Carfilzomib/Lenalidomide and dexamethasone Maintenance : Lenalidomide 13 cycles of 28
      days
    
  